iRhythm Technologies

iRhythm Technologies, Inc. engages in the development of monitoring and diagnostic solutions for detection of cardiac arrhythmias. It offers Zio XT, is a wearable patch-based biosensor, which continuously records and stores ECG data from every patient heartbeat for up to 14 consecutive days, and Zio AT, which provides ECG data but also provides physicians with actionable notifications during the wear period. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

iRhythm Technologies posts robust Q4 earnings, eyes global expansion

iRhythm Technologies delivered strong financial results, showcasing growth, innovation, and a positive EBITDA in Q4 2022. The company faces challenges in managing expenses and enhancing integration but has opportunities in new product launches, international expansion, and operational improvements.

iRhythm Technologies posts strong Q1 earnings amidst growth opportunities

iRhythm Technologies delivered robust Q1 2023 results with strong revenue growth and strategic advancements, positioning the company for sustainable expansion.
While challenges like legal inquiries and narrow profitability margins exist, the company's focus on innovation, market penetration, and financial stability bodes well for future prospects.
By capitalizing on strengths like positive clinical data, scalable growth strategies, and market opportunities, iRhythm Technologies aims to navigate challenges and drive long-term success.

iRhythm Technologies posts record revenue growth amidst regulatory challenges

iRhythm Technologies reported strong revenue growth and international expansion milestones despite challenges with FDA warning and product launch delays.
The company's focus on innovation, patient compliance, and market penetration presents opportunities for future growth and advocacy for proactive screening.
While facing challenges in product development and regulatory compliance, iRhythm remains financially robust and strategically positioned for continued success.
Navigating through challenges, iRhythm is poised to capitalize on growth opportunities and strengthen its position in the cardiac monitoring market.

iRhythm Technologies reports strong Q3 growth and eyes global expansion

iRhythm Technologies demonstrated strong financial performance in Q3 2023, with revenue growth, improved patient engagement, and market acceptance of Zio monitoring.
While facing challenges such as gross margin pressure and pricing concerns, iRhythm is focused on strategic growth initiatives and cost management for sustainable profitability.
The company is well-positioned to capitalize on opportunities like silent AFib monitoring, market expansion in Japan, and leveraging guidelines for wider screening to drive future growth.
Overall, iRhythm's Q3 results reflect resilience, strategic planning, and a positive outlook for continued success in 2023 and beyond.

iRhythm Technologies surpasses revenue expectations, eyes international expansion for growth

iRhythm Technologies demonstrated robust financial performance in Q4 2023, exceeding revenue guidance and showcasing growth in key operational metrics.
Despite regulatory challenges and external factors impacting revenue, the company's strategic strengths in product adoption and clinical evidence position it well for future growth.
Opportunities in AI, proactive screening, international expansion, and market disruption present avenues for continued expansion and market leadership.
Balancing challenges with opportunities, iRhythm aims to maintain financial sustainability while driving growth and innovation in the cardiac monitoring space.

iRhythm Technologies reports strong Q1 earnings, eyes global expansion

iRhythm Technologies delivered robust financial performance in Q1 2024, showcasing revenue growth, strategic partnerships, and a focus on sustainable operating leverage improvements.
While facing challenges such as awaiting FDA clearances and managing short-term financial losses, the company remains well-positioned with a strong financial foundation and global growth prospects.
Opportunities lie in upcoming product launches, market expansions, and the exploration of new adjacencies, positioning iRhythm for continued growth and market leadership.
Overall, iRhythm's emphasis on innovation, market expansion, and operational efficiency sets a positive trajectory for future success and shareholder value creation.

iRhythm Technologies excels in Q2 earnings, eyes global expansion

iRhythm Technologies delivered strong financial performance in Q2 2024, driven by product excellence and market expansion efforts.
While facing challenges with compliance and leadership transitions, the company remains focused on growth and operational effectiveness.
Strategic initiatives in primary care, new markets, and product launches position iRhythm well for future success and revenue growth.

iRhythm Technologies reports robust Q3 growth amidst regulatory advancements

iRhythm Technologies showed strong growth and strategic advancements in Q3 2024, focusing on global expansion and product innovation.
While facing financial challenges and regulatory hurdles, the company is actively addressing quality issues and investing in future growth.
Opportunities in international markets, product development, and financial optimization position iRhythm for long-term success and market leadership.
Investors should monitor iRhythm's progress in addressing challenges and capitalizing on growth opportunities for sustainable value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iRhythm Technologies, Inc. is a digital healthcare company, which engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. It also provides solutions that detect, predict, and prevent disease. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

Investors think that new Medicare payment guidelines will benefit the company.

Why iRhythm Technologies Stock Skyrocketed Today

iRhythm Technologies Inc (NASDAQ: IRTC) commented on the CMS (Centers for Medicare and Medicaid Services) Calendar Year 2022 Medicare Physician Fee Schedule (MPFS) Final Rule. In the Final Rule, CMS did not issue national pricing and continued carrier pricing on Category I CPT codes 93241, 93243, 93245, and 93247 for extended external ECG (electrocardiograph) monitoring, the relevant codes for the Company's Zio XT service.

Why Are iRhythm Shares Soaring Today?

The stock price of iRhythm Technologies Inc (NASDAQ: IRTC) increased by over 25% pre-market today. This is why it happened.

IRTC Stock: Why The Price Surged Today

SAN FRANCISCO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC) (“iRhythm”), a leading digital healthcare solutions company focused on the advancement of cardiac care, today commented on the Centers for Medicare and Medicaid Services (CMS) Calendar Year 2022 Medicare Physician Fee Schedule (MPFS) Final Rule. The Final Rule and accompanying Addenda were released on November 2, 2021, along with updated payment policies, payment rates, and other provisions for services furnished under MPFS on or after January 1, 2022.

iRhythm Technologies Comments on Centers for Medicare and Medicaid Services 2022 Medicare Physician Fee Schedule Final Rule

Brooks Automation

Emerson Electric

IPG Photonics

Kratos Defense & Security Solutions

UiPath

The world is going through a massive logistics meltdown. Automation will be a key part of the solution, making these robotics stocks buys.

7 Robotics Stocks to Buy to Ride the Automation Wave

SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that it will release financial results for the third quarter 2021 after the close of trading on Thursday, November 4, 2021. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.

iRhythm Technologies to Report Third Quarter 2021 Financial Results on November 4, 2021

Karen Ling Appointed to the Board; Raymond Scott to Retire Karen Ling Appointed to the Board; Raymond Scott to Retire

iRhythm® Technologies Announces Changes to Its Board of Directors

The stock price of iRhythm Technologies Inc (NASDAQ: IRTC) increased by over 3% today. This is why it happened.

IRTC Stock: Why It Increased Today

Data published in PLOS One shows continuous monitoring leads to earlier diagnosis and prevents adverse cardiac events, furthering the case for cardiac screening Data published in PLOS One shows continuous monitoring leads to earlier diagnosis and prevents adverse cardiac events, furthering the case for cardiac screening

mSToPS Clinical Trial Demonstrates Zio by iRhythm Significantly Improves Health Outcomes for At-Risk Patient Populations

The stock price of iRhythm Technologies, a healthcare company that provides ambulatory electrocardiogram and cardiac monitoring products, has seen a rise of 27% over the last one month (twenty-one trading days). This can be attributed to the company's announcement of new CEO - Quentin Blackford.

What's Happening With iRhythm Technologies Stock?

iRhythm shares were riding high at the beginning of 2021, priced >$250.

iRhythm: Upside Potential If Reimbursement Issues Can Be Resolved

IRHYTHM TECH (IRTC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

IRHYTHM TECH (IRTC) Moves 35% Higher: Will This Strength Last?

A new CEO with an impressive record is giving investors hope for a rapid turnaround for the heart monitor maker.

Here's Why iRhythm Technologies Stock Is Making Big Gains Today

Irhythm Technologies (IRTC) stock is taking off on Monday after announcing Quentin Blackford as its next CEO and we have more to know. The post IRTC Stock: 7 Things to Know About Digital Healthcare Play iRhythm Technologies as Shares Soar appeared first on InvestorPlace.

IRTC Stock: 7 Things to Know About Digital Healthcare Play iRhythm Technologies as Shares Soar

Accomplished MedTech Leader with Proven Track Record of Strategic, Operational and Financial Execution with High Growth Companies Accomplished MedTech Leader with Proven Track Record of Strategic, Operational and Financial Execution with High Growth Companies

iRhythm® Technologies Names Quentin Blackford President and Chief Executive Officer

SAN FRANCISCO, Aug. 26, 2021 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the company will be participating in the upcoming 19th Annual Morgan Stanley Global Healthcare Conference.

iRhythm® Technologies to Present at the 19th Annual Morgan Stanley Global Healthcare Conference

iRhythm Technologies, Inc. (IRTC) CEO Doug Devine on Q2 2021 Results - Earnings Call Transcript

IRHYTHM TECH (IRTC) delivered earnings and revenue surprises of 39.18% and 11.42%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

IRHYTHM TECH (IRTC) Reports Q2 Loss, Tops Revenue Estimates

IRHYTHM TECH (IRTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate IRHYTHM TECH (IRTC) to Report a Decline in Earnings: What to Look Out for

SAN FRANCISCO, July 22, 2021 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that it will release financial results for the second quarter 2021 after the close of trading on Thursday, August 5, 2021. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.

iRhythm Technologies to Report Second Quarter 2021 Financial Results on August 5, 2021

SAN FRANCISCO, July 14, 2021 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today provided comment on the recently released Centers for Medicare and Medicaid Services (“CMS”) Calendar Year 2022 Medicare Physician Fee Schedule Proposed Rule (the “Proposed Rule”). The Proposed Rule was released on July 13, 2021, and includes proposed, updated payment policies, payment rates, and other provisions for services furnished under the Medicare Physician Fee Schedule (“MPFS”) on or after January 1, 2022. The Proposed Rule is followed by a public comment period which will culminate with CMS' release of a Final Rule, which is expected to be announced by early November for implementation on January 1, 2022. The policies announced in the Proposed Rule are therefore subject to change.

iRhythm® Technologies Comments on the Centers for Medicare and Medicaid Services 2022 Proposed Medicare Physician Fee Schedule

SAN FRANCISCO, July 08, 2021 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, and the Value Based Care Council (VBCC) of the National Association of Managed Care Physicians (NAMCP) today announced a one-of-a-kind partnership to help payers and managed care organizations (MCOs) effectively assess the value of long-term continuous cardiac monitoring.

iRhythm® Technologies and the National Association of Managed Care Physicians Partner to Study the Value of Ambulatory Cardiac Monitoring Solutions

The medical device maker's stock tumbled after it announced that its CEO would be leaving the company.

Why Did iRhythm Technologies Fall 16% in June?

We believe that the stock price of iRhythm Technologies, a healthcare company that provides ambulatory electrocardiogram and cardiac monitoring products, looks undervalued at current levels of around $75. IRTC stock is actually at the same levels it was on March 23, 2020, when broader markets made.

Should You Buy iRhythm Technologies Stock At $75?

President and CEO Michael Coyle Steps Down Due to Personal Matters

News for iRhythm Technologies Stock (IRTC)